Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 27, 2015 8:57 PM ET

Biotechnology

Company Overview of PTC Therapeutics, Inc.

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical developme...

100 Corporate Court

South Plainfield, NJ 07080

United States

Founded in 1998

187 Employees

Phone:

908-222-7000

Fax:

908-222-7231

Key Executives for PTC Therapeutics, Inc.

Co-Founder, Chief Executive Officer and Executive Director
Age: 54
Total Annual Compensation: $460.8K
Chief Commercial Officer
Age: 51
Total Annual Compensation: $368.2K
Compensation as of Fiscal Year 2013.

PTC Therapeutics, Inc. Key Developments

PTC Therapeutics Announces Translarna™ Access Program in Duchenne Muscular Dystrophy for Siblings of Patients Participating in PTC Clinical Trials

PTC Therapeutics, Inc. announced that it will make Translarna available for siblings of patients in certain open label PTC clinical trials for nonsense mutation Duchenne muscular dystrophy (nmDMD). Translarna will be made available to these siblings in advance of commercial availability in their regions, after a treating physician and the patient or guardian make a clinical decision to use Translarna, and consistent with any other applicable regulatory requirements. Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA'sOffice of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

PTC Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 08:00 AM

PTC Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 08:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Tuyen Ong, Senior Vice President and Head of Clinical Development & Translational Research.

PTC Therapeutics, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for the Full Year 2015

PTC Therapeutics, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss and net loss attributable to common shareholders of $27,269,000 or $0.84 per basic and diluted share on total revenues of $12,658,000 against net loss and net loss attributable to common shareholders of $17,885,000 or $0.75 per basic and diluted share on total revenues of $4,411,000 a year ago. Loss from operations of $32,230,000 and loss from operations before tax benefit of $31,962,000 against loss from operations of $18,092,000 and loss from operations before tax benefit of $17,885,000 a year ago. For the full year, the company reported net loss and net loss attributable to common shareholders of $93,753,000 or $2.97 per basic and diluted share on total revenues of $25,245,000 against net loss and net loss attributable to common shareholders of $51,574,000 or $5.18 per basic and diluted share on total revenues of $34,696,000 a year ago. Loss from operations of $99,413,000 and loss from operations before tax benefit of $98,446,000 against loss from operations of $45,398,000 and loss from operations before tax benefit of $51,574,000 a year ago. Operating expense for the full year 2015 is anticipated to be between $160- $170 million, excluding expected non-cash stock-based compensation expense of approximately $30 million, for total operating expenses of approximately $190 million to $200 million. These expenses will be primarily in support of its ongoing and planned confirmatory Phase 3 clinical trials for Translarna in nmDMD and nmCF, commercial launch activities for Translarna in the EU as well as pre-commercial activities in the US, and the continued research and clinical development of other product pipeline candidates.

Similar Private Companies By Industry

Company Name Region
Neogenix Oncology, Inc. United States
Highgate Orthopedics, Inc. United States
Immunotherapy Worldwide United States
Envisia Therapeutics Inc. United States
Imbed Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC Therapeutics, Inc., please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.